Literature DB >> 16619496

P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.

Hidetaka Uramoto1, Kenji Sugio, Tsunehiro Oyama, Takeshi Hanagiri, Kosei Yasumoto.   

Abstract

p53R2 plays a crucial role in supplying dNTPs for DNA repair. The expression of p53R2 is induced by DNA-damaging agents in a p53-dependent manner and p53R2 translocates to the nucleus upon DNA damage. Immunohistochemistry was used to analyze the protein expression of p53R2 in paraffin-embedded tumor samples from 130 well-characterized non-small cell lung cancer (NSCLC) patients and the expression level of p53R2, clinical variables and survival outcome were compared. A positive expression of p53R2 was detected in the cytoplasm of tumor cells in 61 of the 130 patients (46.2%) with NSCLC. The positive ratio was significantly higher in the patients with pathological stage II/III, pathological T3-4 and pathological N1-3 than in those with stage I, T1-2 and N0, respectively. No significant difference was observed between the p53R2 expression and the gender, age at operation, histological type or p53 expression. Though our findings do not support that the p53R2 immunocytochemical marker alone plays an important prognostic role in NSCLC, the DNA repair pathway mediated by p53R2 may be responsible for controlling the growth of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619496

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.

Authors:  Xiyong Liu; Lily Lai; Xiaochen Wang; Lijun Xue; Sofia Leora; Jun Wu; Shuya Hu; Keqiang Zhang; Mei-Ling Kuo; Lun Zhou; Hang Zhang; Yafan Wang; Yan Wang; Bingsen Zhou; Rebecca A Nelson; Shu Zheng; Suzhan Zhang; Peiguo Chu; Yun Yen
Journal:  Cancer Res       Date:  2011-03-17       Impact factor: 12.701

2.  E2F1 regulates p53R2 gene expression in p53-deficient cells.

Authors:  Jun-Juan Qi; Ling Liu; Ji-Xiang Cao; Guo-Shun An; Shu-Yan Li; Gang Li; Hong-Ti Jia; Ju-Hua Ni
Journal:  Mol Cell Biochem       Date:  2014-10-14       Impact factor: 3.396

3.  p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer.

Authors:  Nan-Yung Hsu; Jeng-Yuan Wu; Xiyong Liu; Yun Yen; Chih-Yi Chen; Ming-Chih Chou; Huei Lee; Ya-Wen Cheng
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

Review 4.  Nucleotide metabolism, oncogene-induced senescence and cancer.

Authors:  Katherine M Aird; Rugang Zhang
Journal:  Cancer Lett       Date:  2014-01-29       Impact factor: 8.679

5.  DGCR8/ZFAT-AS1 Promotes CDX2 Transcription in a PRC2 Complex-Dependent Manner to Facilitate the Malignant Biological Behavior of Glioma Cells.

Authors:  Fangfang Zhang; Xuelei Ruan; Jun Ma; Xiaobai Liu; Jian Zheng; Yunhui Liu; Libo Liu; Shuyuan Shen; Lianqi Shao; Di Wang; Chunqing Yang; Heng Cai; Zhen Li; Ziyi Feng; Yixue Xue
Journal:  Mol Ther       Date:  2019-11-20       Impact factor: 11.454

6.  p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.

Authors:  Keqiang Zhang; Jun Wu; Xiwei Wu; Xiaochen Wang; Yan Wang; Ning Zhou; Mei-ling Kuo; Xiyong Liu; Bingsen Zhou; Lufen Chang; David Ann; Yun Yen
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

Review 7.  Still no Rest for the Reductases: Ribonucleotide Reductase (RNR) Structure and Function: An Update.

Authors:  Marcus J C Long; Phillippe Ly; Yimon Aye
Journal:  Subcell Biochem       Date:  2022

Review 8.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

9.  Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.

Authors:  Francesco Grossi; Maria Giovanna Dal Bello; Sandra Salvi; Roberto Puzone; Ulrich Pfeffer; Vincenzo Fontana; Angela Alama; Erika Rijavec; Giulia Barletta; Carlo Genova; Claudio Sini; Giovanni Battista Ratto; Mario Taviani; Mauro Truini; Domenico Franco Merlo
Journal:  Dis Markers       Date:  2015-11-17       Impact factor: 3.434

10.  Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.

Authors:  Charlotte L T Jørgensen; Bent Ejlertsen; Karsten D Bjerre; Eva Balslev; Dorte L Nielsen; Kirsten V Nielsen
Journal:  BMC Cancer       Date:  2013-11-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.